IP Library › Granted Patent US 12,331,105

Granted Patent B2

US 12,331,105 · App. 17/677,757 · Granted Jun 17, 2025

Broadly neutralizing antibodies against HIV

Inventors: Mohammad Sajadi (Cockeysville, MD); George K. Lewis (Baltimore, MD); Anthony DeVico (Alexandria, VA); Dongkyoon Kim (Palo Alto, CA); Guy Cavet (Hillsborough, CA)

Assignees: University of Maryland, Baltimore; The United States Government as Represented by the Department of Veterans Affairs

C07K16/1063 A61K39/42 A61K45/06 A61P31/18 C07K16/1045 C07K2317/34 C07K2317/565 C07K2317/732 C07K2317/76 C07K2317/92 C07K2317/94

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,331,105
App. No.: 17/677,757
Granted: Jun 17, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention provides broadly neutralizing antibodies against HIV, compositions comprising the same and methods of use thereof.

Claims (71)

1. A non-naturally occurring anti-HIV antibody, wherein the anti-HIV antibody is selected from the group consisting of:

a. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYKFPDYI (SEQ ID NO:405), CDR H2 comprises INPMGGQV (SEQ ID NO:406) and CDR H3 comprises VRDRSNGSGRRFESSN (SEQ ID NO: 407); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO: 408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:5 and a light chain amino acid sequence of SEQ ID NO:6;

b. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises IDPPYGQV (SEQ ID NO:414) and CDR H3 comprises VRDRSNGWGKRFESSNWFLDL (SEQ ID NO:415); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:9 and a light chain amino acid sequence of SEQ ID NO:10;

c. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFVDYF (SEQ ID NO:416), CDR H2 comprises MDPLNGRP (SEQ ID NO:417) and CDR H3 comprises VRDKSNGSGRRFDSSNWFLDL (SEQ ID NO:418); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:13 and a light chain amino acid sequence of SEQ ID NO:14;

d. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFSDYI (SEQ ID NO:420), CDR H2 comprises MNPMGGQV (SEQ ID NO:421) and CDR H3 comprises VRDRSNGSGKRFESSNWFLDL (SEQ ID NO:441); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEV (SEQ ID NO:422), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:15 and a light chain amino acid sequence of SEQ ID NO:16;

e. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFIDYI (SEQ ID NO:423), CDR H2 comprises IDPMNGRP (SEQ ID NO:424) and CDR H3 comprises VRDKSNGSGKRFDSSNWFLDL (SEQ ID NO:425); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:17 and a light chain amino acid sequence of SEQ ID NO:18;

f. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTDYI (SEQ ID NO:426), CDR H2 comprises MNPMGGRT (SEQ ID NO:427) and CDR H3 comprises VRDKSNGSGKRFDSSNWFLDL (SEQ ID NO:425); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:19 and a light chain amino acid sequence of SEQ ID NO:20;

g. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFVDYL (SEQ ID NO:428), CDR H2 comprises MDPMNGRP (SEQ ID NO:429) and CDR H3 comprises VRDKSGGSGKLFDSSNWFLDL (SEQ ID NO:430); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 21 and a light chain amino acid sequence of SEQ ID NO:22;

h. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises INPGYGQV (SEQ ID NO:431) and CDR H3 comprises VRDRSNGWGKRFESSNWFLDL (SEQ ID NO:415); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DEN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 23 and a light chain amino acid sequence of SEQ ID NO:24;

i. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises MDPSYGQV (SEQ ID NO:432) and CDR H3 comprises VRDRSHGSGRQFESSNWFLDL (SEQ ID NO:433); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:25 and a light chain amino acid sequence of SEQ ID NO:26;

j. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises MDPSFGQM (SEQ ID NO:434) and CDR H3 comprises VRDRSHGSGRLFESSNWFLDL (SEQ ID NO:435); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:27 and a light chain amino acid sequence of SEQ ID NO:28;

k. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYRFTDYV (SEQ ID NO:436), CDR H2 comprises MDPSFGRM (SEQ ID NO:437) and CDR H3 comprises VRDRSHGSGRLFESSNWFLDL (SEQ ID NO:435); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:29 and a light chain amino acid sequence of SEQ ID NO:30;

l. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFIDYV (SEQ ID NO:438), CDR H2 comprises MDPTYGRM (SEQ ID NO:439) and CDR H3 comprises VRDRSHGSGRLFESSNWFLDL (SEQ ID NO:435); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:31 and a light chain amino acid sequence of SEQ ID NO:32;

m. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYRFLDYI (SEQ ID NO:440), CDR H2 comprises MNPMGGQV (SEQ ID NO:421) and CDR H3 comprises VRDRSNGSGKRFESSNWFLDL (SEQ ID NO:441); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:33 and a light chain amino acid sequence of SEQ ID NO 34;

n. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYNFVDSR (SEQ ID NO:447), CDR H2 comprises INPLQGGV (SEQ ID NO:448) and CDR H3 comprises ARGIDGKSYPFHF (SEQ ID NO: 449); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises ESS and CDR L3 comprises SILEF (SEQ ID NO:450), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:37 and a light chain amino acid sequence of SEQ ID NO:38;

o. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTTHHGHF (SEQ ID NO:500), CDR H2 comprises MNPMTGQM (SEQ ID NO:462) and CDR H3 comprises ARGDFGQNYPFHY (SEQ ID NO:463); and a light chain variable region, wherein CDR L1 comprises NRYL (SEQ ID NO:464), CDR L2 comprises DDN and CDR L3 comprises ASYER (SEQ ID NO:465), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:39 and a light chain amino acid sequence of SEQ ID NO:40;

p. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYNFMDQF (SEQ ID NO:466), CDR H2 comprises MNPIYGQV (SEQ ID NO:467) and CDR H3 comprises ARGPSGENYPFHY (SEQ ID NO: 444); and a light chain variable region, wherein CDR L1 comprises RHII (SEQ ID NO:445), CDR L2 comprises DDD and CDR L3 comprises NTYEF (SEQ ID NO:446), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:41 and a light chain amino acid sequence of SEQ ID NO:42;

q. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYNFVDSR (SEQ ID NO:447), CDR H2 comprises INPLHGGV (SEQ ID NO:468) and CDR H3 comprises ARGIDGKSYPFHF (SEQ ID NO: 449); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises ESS and CDR L3 comprises SILEF (SEQ ID NO:450), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:43 and a light chain amino acid sequence of SEQ ID NO:44;

r. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTKYF (SEQ ID NO:451), CDR H2 comprises IHPRTGAV (SEQ ID NO:452) and CDR H3 comprises ARGAFEADSYGSSYPFHH (SEQ ID NO:453); and a light chain variable region, wherein CDR L1 comprises GNYNP (SEQ ID NO:454), CDR L2 comprises EDN and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:45 and a light chain amino acid sequence of SEQ ID NO:46;

s. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTKYT (SEQ ID NO:456), CDR H2 comprises IHPRTGAV (SEQ ID NO:452) and CDR H3 comprises ARGAFEADLSGPTYPFHH (SEQ ID NO:457); and a light chain variable region, wherein CDR L1 comprises GNYNP (SEQ ID NO:454), CDR L2 comprises EDN and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:47 and a light chain amino acid sequence of SEQ ID NO:48;

t. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFNFIDSV (SEQ ID NO:458), CDR H2 comprises IKPLRGAV (SEQ ID NO:459) and CDR H3 comprises AKGAFRGGSPFGF (SEQ ID NO: 460); and a light chain variable region, wherein CDR L1 comprises DVT and CDR L2 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 49 and a light chain amino acid sequence of SEQ ID NO:50;

u. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTSYF (SEQ ID NO:469), CDR H2 comprises INPLHGAV (SEQ ID NO:470) and CDR H3 comprises TRGIVADGWPYGH (SEQ ID NO: 471); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises EGA and CDR L3 comprises SSLQF (SEQ ID NO:472), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:51 and a light chain amino acid sequence of SEQ ID NO:52;

v. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFTFIDHI (SEQ ID NO:473), CDR H2 comprises IKPLRGAV (SEQ ID NO:459) and CDR H3 comprises CKAAAPEEAFPLQY (SEQ ID NO: 474); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSRTF (SEQ ID NO:475), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:53 and a light chain amino acid sequence of SEQ ID NO:54;

w. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFKFIDHI (SEQ ID NO:476), CDR H2 comprises IKPLGGVA (SEQ ID NO:477) and CDR H3 comprises CKAAAPDEAFPLEY (SEQ ID NO: 478); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO:479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:55 and a light chain amino acid sequence of SEQ ID NO:56;

x. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFAFLDH (SEQ ID NO:480), CDR H2 comprises VKTIGGVV (SEQ ID NO:481) and CDR H3 comprises SKAAAPDEAFPLEF (SEQ ID NO: 482); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO:479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:57 and a light chain amino acid sequence of SEQ ID NO:58;

y. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFKFTEYF (SEQ ID NO:483), CDR H2 comprises LNPLRGAV (SEQ ID NO:484) and CDR H3 comprises ARAVFNEAFPFDY (SEQ ID NO: 485); and a light chain variable region, wherein CDR L1 comprises VS, CDR L2 comprises DGD and CDR L3 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:61 and a light chain amino acid sequence of SEQ ID NO:62;

z. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFKFIDHI (SEQ ID NO:476), CDR H2 comprises IKPLGGVA (SEQ ID NO:477) and CDR H3 comprises CKAAAPDEAFPLEY (SEQ ID NO: 478); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DND and CDR L3 comprises SSTTF (SEQ ID NO:479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:63 and a light chain amino acid sequence of SEQ ID NO:64;

aa. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFAFLDHI (SEQ ID NO:486), CDR H2 comprises VKTIGGVV (SEQ ID NO:481) and CDR H3 comprises SKAAAPDEAFPLEF (SEQ ID NO: 482); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO:479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:65 and a light chain amino acid sequence of SEQ ID NO:66;

bb. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFKFIDSV (SEQ ID NO:487), CDR H2 comprises IKPLGGAV (SEQ ID NO:488) and CDR H3 comprises AKGAFGGGSPFGF (SEQ ID NO: 489); and a light chain variable region, wherein CDR L1 comprises DVT and CDR L2 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 67 and a light chain amino acid sequence of SEQ ID NO:68;

cc. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFNFIDSV (SEQ ID NO:458), CDR H2 comprises IKPLRGGV (SEQ ID NO:490) and CDR H3 comprises AKGAFGGSSPFGF (SEQ ID NO: 491); and a light chain variable region, wherein CDR L1 comprises DVT and CDR L2 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 69 and a light chain amino acid sequence of SEQ ID NO:70;

dd. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFTFIKYT (SEQ ID NO:492), CDR H2 comprises IHPRTGAV (SEQ ID NO:452) and CDR H3 comprises ARGAFEADLYGPTYPFHH (SEQ ID NO:493); and a light chain variable region, wherein CDR L1 comprises GSYNP (SEQ ID NO:494), CDR L2 comprises DDN and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:73 and a light chain amino acid sequence of SEQ ID NO:74;

ee. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYNFVDSL (SEQ ID NO:495), CDR H2 comprises INPLQGGV (SEQ ID NO:448) and CDR H3 comprises ARGIDGNSYPFHF (SEQ ID NO: 496); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises ESS and CDR L3 comprises SILEF (SEQ ID NO:450), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:75 and a light chain amino acid sequence of SEQ ID NO:76;

ff. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYRFPDYI (SEQ ID NO:497), CDR H2 comprises MNPMGGQV (SEQ ID NO:421) and CDR H3 comprises VRDRSNGSGKRFESSNWFLDL (SEQ ID NO:441); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419);

gg. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFAFLDHI (SEQ ID NO:486), CDR H2 comprises VKTIGGVV (SEQ ID NO:481) and CDR H3 comprises SKAAAPDEAFPLEF (SEQ ID NO:482); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO:479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:59 and a light chain amino acid sequence of SEQ ID NO:60; and

hh. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GFNFIDSV (SEQ ID NO:458), CDR H2 comprises IKPLRGGV (SEQ ID NO:490) and CDR H3 comprises AKGAFGGSSPFGF (SEQ ID NO:491); and a light chain variable region, wherein CDR L2 comprises DVT and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:71 and a light chain amino acid sequence of SEQ ID NO: 72.

2. A pharmaceutical composition comprising one or more anti-HIV antibodies of claim 1 , and a pharmaceutically acceptable carrier.

3. A method for treating HIV infection in a subject, comprising administering to the subject infected with HIV an effective amount of the composition of claim 1 .

4. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYKFPDYI (SEQ ID NO:405), CDR H2 comprises INPMGGQV (SEQ ID NO:406) and CDR H3 comprises VRDRSNGSGRRFESSN (SEQ ID NO:407); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:5 and a light chain amino acid sequence of SEQ ID NO:6.

5. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises IDPPYGQV (SEQ ID NO:414) and CDR H3 comprises VRDRSNGWGKRFESSNWFLDL (SEQ ID NO:415); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 9 and a light chain amino acid sequence of SEQ ID NO:10.

6. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFVDYF (SEQ ID NO:416), CDR H2 comprises MDPLNGRP (SEQ ID NO:417) and CDR H3 comprises VRDKSNGSGRRFDSSNWFLDL (SEQ ID NO:418); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 13 and a light chain amino acid sequence of SEQ ID NO:14.

7. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFSDYI (SEQ ID NO:420), CDR H2 comprises MNPMGGQV (SEQ ID NO:421) and CDR H3 comprises VRDRSNGSGKRFESSNWFLDL (SEQ ID NO:441); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEV (SEQ ID NO:422), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 15 and a light chain amino acid sequence of SEQ ID NO:16.

8. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFIDYI (SEQ ID NO:423), CDR H2 comprises IDPMNGRP (SEQ ID NO:424) and CDR H3 comprises VRDKSNGSGKRFDSSNWFLDL (SEQ ID NO:425); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 17 and a light chain amino acid sequence of SEQ ID NO:18.

9. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTDYI (SEQ ID NO:426), CDR H2 comprises MNPMGGRT (SEQ ID NO:427) and CDR H3 comprises VRDKSNGSGKRFDSSNWFLDL (SEQ ID NO:425); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 19 and a light chain amino acid sequence of SEQ ID NO:20.

10. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFVDYL (SEQ ID NO:428), CDR H2 comprises MDPMNGRP (SEQ ID NO:429) and CDR H3 comprises VRDKSGGSGKLFDSSNWFLDL (SEQ ID NO:430); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 21 and a light chain amino acid sequence of SEQ ID NO:22.

11. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises INPGYGQV (SEQ ID NO:431) and CDR H3 comprises VRDRSNGWGKRFESSNWFLDL (SEQ ID NO:415); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 23 and a light chain amino acid sequence of SEQ ID NO:24.

12. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises MDPSYGQV (SEQ ID NO:432) and CDR H3 comprises VRDRSHGSGRQFESSNWFLDL (SEQ ID NO:433); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 25 and a light chain amino acid sequence of SEQ ID NO:26.

13. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTDYV (SEQ ID NO:413), CDR H2 comprises MDPSFGQM (SEQ ID NO:434) and CDR H3 comprises VRDRSHGSGRLFESSNWFLDL (SEQ ID NO:435); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 27 and a light chain amino acid sequence of SEQ ID NO:28.

14. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYRFTDYV (SEQ ID NO:436), CDR H2 comprises MDPSFGRM (SEQ ID NO:437) and CDR H3 comprises VRDRSHGSGRLFESSNWFLDL (SEQ ID NO:435); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 29 and a light chain amino acid sequence of SEQ ID NO:30.

15. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFIDYV (SEQ ID NO:438), CDR H2 comprises MDPTYGRM (SEQ ID NO:439) and CDR H3 comprises VRDRSHGSGRLFESSNWFLDL (SEQ ID NO:435); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 31 and a light chain amino acid sequence of SEQ ID NO:32.

16. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYRFLDYI (SEQ ID NO:440), CDR H2 comprises MNPMGGQV (SEQ ID NO:421) and CDR H3 comprises VRDRSNGSGKRFESSNWFLDL (SEQ ID NO:441); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DFN and CDR L3 comprises WAYEA (SEQ ID NO:408), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 33 and a light chain amino acid sequence of SEQ ID NO 34.

17. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYNFVDSR (SEQ ID NO:447), CDR H2 comprises INPLQGGV (SEQ ID NO:448) and CDR H3 comprises ARGIDGKSYPFHF (SEQ ID NO: 449); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises ESS and CDR L3 comprises SILEF (SEQ ID NO:450), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:37 and a light chain amino acid sequence of SEQ ID NO:38.

18. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTTHHGHF (SEQ ID NO:500), CDR H2 comprises MNPMTGQM (SEQ ID NO:462) and CDR H3 comprises ARGDFGQNYPFHY (SEQ ID NO:463); and a light chain variable region, wherein CDR L1 comprises NRYL (SEQ ID NO:464), CDR L2 comprises DDN and CDR L3 comprises ASYER (SEQ ID NO:465), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:39 and a light chain amino acid sequence of SEQ ID NO: 40.

19. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYNFMDQF (SEQ ID NO:466), CDR H2 comprises MNPIYGQV (SEQ ID NO:467) and CDR H3 comprises ARGPSGENYPFHY (SEQ ID NO:444); and a light chain variable region, wherein CDR L1 comprises RHII (SEQ ID NO:445), CDR L2 comprises DDD and CDR L3 comprises NTYEF (SEQ ID NO:446), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:41 and a light chain amino acid sequence of SEQ ID NO: 42.

20. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYNFVDSR (SEQ ID NO:447), CDR H2 comprises INPLHGGV (SEQ ID NO:468) and CDR H3 comprises ARGIDGKSYPFHF (SEQ ID NO: 449); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises ESS and CDR L3 comprises SILEF (SEQ ID NO:450), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:43 and a light chain amino acid sequence of SEQ ID NO:44.

21. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTKYF (SEQ ID NO:451), CDR H2 comprises IHPRTGAV (SEQ ID NO:452) and CDR H3 comprises ARGAFEADSYGSSYPFHH (SEQ ID NO:453); and a light chain variable region, wherein CDR L1 comprises GNYNP (SEQ ID NO:454), CDR L2 comprises EDN and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 45 and a light chain amino acid sequence of SEQ ID NO:46.

22. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTKYT (SEQ ID NO:456), CDR H2 comprises IHPRTGAV (SEQ ID NO:452) and CDR H3 comprises ARGAFEADLSGPTYPFHH (SEQ ID NO:457); and a light chain variable region, wherein CDR L1 comprises GNYNP (SEQ ID NO:454), CDR L2 comprises EDN and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 47 and a light chain amino acid sequence of SEQ ID NO:48.

23. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFNFIDSV (SEQ ID NO:458), CDR H2 comprises IKPLRGAV (SEQ ID NO:459) and CDR H3 comprises AKGAFRGGSPFGF (SEQ ID NO: 460); and a light chain variable region, wherein CDR L1 comprises DVT and CDR L2 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 49 and a light chain amino acid sequence of SEQ ID NO:50.

24. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYTFTSYF (SEQ ID NO:469), CDR H2 comprises INPLHGAV (SEQ ID NO:470) and CDR H3 comprises TRGIVADGWPYGH (SEQ ID NO: 471); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises EGA and CDR L3 comprises SSLQF (SEQ ID NO:472), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:51 and a light chain amino acid sequence of SEQ ID NO:52.

25. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFTFIDHI (SEQ ID NO:473), CDR H2 comprises IKPLRGAV (SEQ ID NO:459) and CDR H3 comprises CKAAAPEEAFPLQY (SEQ ID NO: 474); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSRTF (SEQ ID NO: 475), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:53 and a light chain amino acid sequence of SEQ ID NO:54.

26. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFKFIDHI (SEQ ID NO:476), CDR H2 comprises IKPLGGVA (SEQ ID NO:477) and CDR H3 comprises CKAAAPDEAFPLEY (SEQ ID NO: 478); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO: 479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:55 and a light chain amino acid sequence of SEQ ID NO:56.

27. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFAFLDH (SEQ ID NO:480), CDR H2 comprises VKTIGGVV (SEQ ID NO:481) and CDR H3 comprises SKAAAPDEAFPLEF (SEQ ID NO: 482); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO: 479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:57 and a light chain amino acid sequence of SEQ ID NO:58.

28. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFKFTEYF (SEQ ID NO:483), CDR H2 comprises LNPLRGAV (SEQ ID NO:484) and CDR H3 comprises ARAVFNEAFPFDY (SEQ ID NO: 485); and a light chain variable region, wherein CDR L1 comprises VS, CDR L2 comprises DGD and CDR L3 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:61 and a light chain amino acid sequence of SEQ ID NO:62.

29. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFKFIDHI (SEQ ID NO:476), CDR H2 comprises IKPLGGVA (SEQ ID NO:477) and CDR H3 comprises CKAAAPDEAFPLEY (SEQ ID NO: 478); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DND and CDR L3 comprises SSTTF (SEQ ID NO: 479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:63 and a light chain amino acid sequence of SEQ ID NO:64.

30. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFAFLDHI (SEQ ID NO:486), CDR H2 comprises VKTIGGVV (SEQ ID NO:481) and CDR H3 comprises SKAAAPDEAFPLEF (SEQ ID NO: 482); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO: 479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:65 and a light chain amino acid sequence of SEQ ID NO:66.

31. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFKFIDSV (SEQ ID NO:487), CDR H2 comprises IKPLGGAV (SEQ ID NO:488) and CDR H3 comprises AKGAFGGGSPFGF (SEQ ID NO: 489); and a light chain variable region, wherein CDR L1 comprises DVT and CDR L2 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 67 and a light chain amino acid sequence of SEQ ID NO:68.

32. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFNFIDSV (SEQ ID NO:458), CDR H2 comprises IKPLRGGV (SEQ ID NO:490) and CDR H3 comprises AKGAFGGSSPFGF (SEQ ID NO: 491); and a light chain variable region, wherein CDR L1 comprises DVT and CDR L2 comprises ASREF (SEQ ID NO:461), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 69 and a light chain amino acid sequence of SEQ ID NO:70.

33. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFTFIKYT (SEQ ID NO:492), CDR H2 comprises IHPRTGAV (SEQ ID NO:452) and CDR H3 comprises ARGAFEADLYGPTYPFHH (SEQ ID NO:493); and a light chain variable region, wherein CDR L1 comprises GSYNP (SEQ ID NO:494), CDR L2 comprises DDN and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 73 and a light chain amino acid sequence of SEQ ID NO:74.

34. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYNFVDSL (SEQ ID NO:495), CDR H2 comprises INPLQGGV (SEQ ID NO:448) and CDR H3 comprises ARGIDGNSYPFHF (SEQ ID NO: 496); and a light chain variable region, wherein CDR L1 comprises S, CDR L2 comprises ESS and CDR L3 comprises SILEF (SEQ ID NO:450), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:75 and a light chain amino acid sequence of SEQ ID NO:76.

35. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GYRFPDYI (SEQ ID NO:497), CDR H2 comprises MNPMGGQV (SEQ ID NO:421) and CDR H3 comprises VRDRSNGSGKRFESSNWFLDL (SEQ ID NO:441); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFN and CDR L3 comprises WAYDA (SEQ ID NO:419).

36. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFAFLDHI (SEQ ID NO:486), CDR H2 comprises VKTIGGVV (SEQ ID NO:481) and CDR H3 comprises SKAAAPDEAFPLEF (SEQ ID NO: 482); and a light chain variable region, wherein CDR L1 comprises NVD, CDR L2 comprises DNN and CDR L3 comprises SSTTF (SEQ ID NO: 479), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO:59 and a light chain amino acid sequence of SEQ ID NO:60.

37. The anti-HIV antibody of claim 1 , wherein the anti-HIV antibody comprises a heavy chain variable region, wherein CDR H1 comprises GFNFIDSV (SEQ ID NO:458), CDR H2 comprises IKPLRGGV (SEQ ID NO:490) and CDR H3 comprises AKGAFGGSSPFGF (SEQ ID NO: 491); and a light chain variable region, wherein CDR L2 comprises DVT and CDR L3 comprises ASFEF (SEQ ID NO:455), wherein the antibody is not an antibody that consists of a heavy chain amino acid sequence of SEQ ID NO: 71 and a light chain amino acid sequence of SEQ ID NO:72.

Continuity (7)

Continuation 16626163

Provisional Application 62673607 · May 18, 2018

Provisional Application 62591244 · Nov 28, 2017

Provisional Application 62589614 · Nov 22, 2017

Provisional Application 62573764 · Oct 18, 2017

Provisional Application 62523437 · Jun 22, 2017

Related Publication 20230002480A1 · Jan 5, 2023

References Cited (79)

US 5237053A · Dorner · 1993 [cited by applicant]

US 5464759A · Coolidge · 1995 [cited by applicant]

US 6180370B1 · Queen · 2001 [cited by examiner]

US 7378093B2 · Dimitrov · 2008 [cited by applicant]

US 9115399B2 · Panigrahi · 2015 [cited by applicant]

US 9146241B2 · Lavinder · 2015 [cited by applicant]

US 9493549B2 · Diskin · 2016 [cited by applicant]

US 9695230B2 · Kwong · 2017 [cited by examiner]

US 20110223615A1 · Lewis · 2011 [cited by applicant]

US 20130251726A1 · Mascola · 2013 [cited by applicant]

US 20140328862A1 · Scheid · 2014 [cited by applicant]

US 20150011405A1 · DeFalco et al. · 2015 [cited by applicant]

US 20160034639A1 · Reddy et al. · 2016 [cited by applicant]

US 20160289305A1 · Mascola et al. · 2016 [cited by applicant]

US 20200172601A1 · Sajadi · 2020 [cited by applicant]

US 20200182883A1 · Sajadi · 2020 [cited by applicant]

US 20200239551A1 · Sajadi · 2020 [cited by applicant]

US 20210040184A1 · Cavet et al. · 2021 [cited by applicant]

WO 1994018232A1 · 1994 [cited by applicant]

WO 2005030123A2 · 2005 [cited by applicant]

WO 2005077106A3 · 2005 [cited by applicant]

WO 2009046984A1 · 2009 [cited by applicant]

WO 2012148497A2 · 2012 [cited by applicant]

WO WO2013016468A2 · 2013 [cited by examiner]

WO 2013078455A2 · 2013 [cited by applicant]

WO 2013090644A2 · 2013 [cited by applicant]

WO 2013185180A1 · 2013 [cited by applicant]

WO 2016154003A1 · 2016 [cited by applicant]

WO 2017205694A1 · 2017 [cited by applicant]

WO 2018237357A1 · 2018 [cited by applicant]

WO 2019067805A1 · 2019 [cited by applicant]

WO 2019165122A1 · 2019 [cited by applicant]

WO 2019173794A1 · 2019 [cited by applicant]

WO 2019173801A1 · 2019 [cited by applicant]

WO WO2019173802A1 · 2019 [cited by examiner]

Sajadi, Mohammad M., et al. “Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.” Journal of virology 86.9 (2012): 5014-5025.. (Year: 2012). [cited by examiner]

Sajadi, Mohammad Mohseni, et al. “Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses.” Cell 173.7 (2018): 1783-1795.. (Year: 2018). [cited by examiner]

Kipriyanov, Sergey M., and Fabrice Le Gall. “Generation and production of engineered antibodies.” Molecular biotechnology 26.1 (2004): 39-60. (Year: 2004). [cited by examiner]

Janeway, A. C., et al. “Immunobiology: the immune system in health and disease. London.” Current Biology (1997): 3:1-3:11. (Year: 1997). [cited by examiner]

International Search Report from Appl. No. PCT/US2018/039162, mailed on Oct. 2, 2018. [cited by applicant]

Shcherbakov et al., Broadly Neutralizing Antibodies against HIV-1 as a Novel Aspect of the Immune Response, Acta Naturae, (2015), vol. 7, p. 11-21. [cited by applicant]

Sajadi et al., Signature Biochemical Properties of Broadly Cross-Reactive HIV-1 Neutralizing Antibodies in Human Plasma, J Virol., (2012), vol. 86, p. 5014-5025. [cited by applicant]

Eroshkin et al., bNAber: database of broadly neutralizing HIV antibodies, Nucleic Acids Research, (2014), vol. 42, p. D1133-D1139. [cited by applicant]

UnitProtKB_A0A0K2DDS5, Methyltransferase. Entry Name: A0A0K2DDS5_9RHIZ. Accession No. A0A0K2DDS5. last modified: Nov. 11, 2015. Retrieved on Sep. 5, 2018. URL: https://www.uniprot.org/uniprot/A0A0K2DDS5> Protein; Access… [cited by applicant]

UnitProtKB_S0KM22, 6-phospho-beta-glucosidase. Entry Name: S0KM22_9ENTE. Accession Number. S0KM22. Last modified: Sep. 18, 2013. Retrieved on Sep. 5, 2018. URL https://www.uniprot.org/uniprot/S0KM22> Protein; Accession … [cited by applicant]

UnitProtKB_A0A151HET4, Uncharacterized protein. Entry Name: A0A151HET4_TOXGO. Accession Number. A0A151HET4. Last modified: Jun. 8, 2016. Retrieved on Sep. 5, 2018. URL: https://www.uniprot.org/uniprot/A0A151HET4> Protei… [cited by applicant]

UnitProtKB_N1JM12. Uncharacterized protein. Entry Name: N1JM12_BLUG1. Accession No. N1JM12. Last Modified: Jun. 26, 2013. Retrieved on Sep. 5, 2018. URL: https//www.uniprot.org/uniprot/N1JM12> Protein; Accession Number;… [cited by applicant]

Sok et al., HIV Broadly Neutralizing Antibodies: Taking Good care of the 98%, Immunity, (2016), vol. 45, p. 958-960. [cited by applicant]

European Extended Search Report from Appl. No. EP17803634, mailed on Dec. 18, 2019. [cited by applicant]

Sato et al., Proteomics-directed cloning of circulating antiviral human monoclanal antibodies, Nature Biotechnology, vol. 30, (2012), p. 1039-1043. [cited by applicant]

Wine et al., Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response, Proceedings of the National Academy of Sciences, vol. 110 (2013), p. 2993-2998. [cited by applicant]

Cheung et al., A proteomics approach for the identification and cloning of monoclonal antibodies form serum, Nature Biotechnology, (2012), p. 1087-0156. [cited by applicant]

Wang et al., Antigen identification and characterization of lung cancer specific monoclonal antibodies produced by mAb proteomics, Journal of Proteome Research, American Chemical Society, vol. 9, (2010), p. 1834-1842. [cited by applicant]

Extended European Search Report from Appl. No. EP 18820469.7, mailed on May 21, 2021. [cited by applicant]

Montezuma-Rusca, Bone Marrow Plasma Cells Are a Primary Source of Serum HIV-1-Specific Antibodies in Chronically Infected Individuals, Jimmunol, (2015), p. 1-12. [cited by applicant]

Sajadi et al., Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity, J Acquir Immune Defic Syndr, (2011) p. 57:9-15. [cited by applicant]

Sajadi et al., λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies, J Infect Dis, (2016) 213:156-164. [cited by applicant]

Robinson, Sequencing the functional antibody repertoire—diagnostic and therapeutic discovery, Nat Rev Rheumatol, (2015), 11(3):171-182. [cited by applicant]

Bashford-Rogers et al., Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods, BMC Immunology, (2014), p. 15(29): 1-9. [cited by applicant]

Kumar et al., CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations, Leukemia, (2005)19:1466-1470. [cited by applicant]

Huang et al., Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth, Immunity, (2016), 45:1108-1121. [cited by applicant]

Huang et al., Broad and potent neutralization of HIV-1 by a gp41-specific human antibody, nature, (2012), 491:406-412. [cited by applicant]

Sajadi et al., Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses, Cell, (2018) 173: 1783-1795. [cited by applicant]

Dashti et al., Broadly Neutralizing Antibodies against HIV: Back to Blood, Trends in Molecular Medicine, (2019), 25:228-240. [cited by applicant]

Supplementary Partial European Search Report from Appl. No. EP 18820469.7, mailed on Feb. 9, 2021. [cited by applicant]

Supplementary European Search Report from Appl. No. 19764362, mailed on Nov. 5, 2021. [cited by applicant]

Scheepers et al., Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses, AIDS, (2017), 31:2199-2209. [cited by applicant]

Supplemental information, Identification of Neal-Pan-neutralizing Antibodies againts HIV-1 by deconvolution of Plasma Humoral Responses, Cell. (2018), p. 1-7, XP55855060. [cited by applicant]

Sajadi, [cited by applicant]

Huang Jinghe et al., Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth, Immunity, (2016) 45:1108-1121, XP029809256. [cited by applicant]

Huang Jinghe et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody, Nature, (2012) 491:406-412, XP055134187. [cited by applicant]

Tomoyuki Igawa et al., Engineering the variable region of therapeutic IgG antibodies, MABS, (2011), 3:243-252, XP055532826. [cited by applicant]

International Search Report from Appl. No. PCT/US19/21495, mailed on Aug. 6, 2019. [cited by applicant]

International Search Report from Appl. No. PCT/US19/21493, mailed on Aug. 12, 2019. [cited by applicant]

International Search Report from Appl. No. PCT/US19/21486, mailed on Aug. 12, 2019. [cited by applicant]

Office Action from Appl. No. U.S. Appl. No. 16/626,163, mailed on Aug. 31, 2021. [cited by applicant]

Office Action from Appl. No. U.S. Appl. No. 16/725,596 mailed on Apr. 29, 2021. [cited by applicant]

Office Action from Appl. No. U.S. Appl. No. 16/725,596 mailed on Feb. 17, 2022. [cited by applicant]